A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate two dosing regimens of subcutaneous Nivolumab in combination with intravenous Ipilimumab and chemotherapy in participants with previously untreated metastatic or recurrent Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
DRUG: Nivolumab|DRUG: Ipilimumab|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Pemetrexed|DRUG: Cisplatin
Maximum observed serum concentration (Cmax) of subcutaneous Nivolumab in serum, Up to 3 weeks|Time to peak concentration (Tmax) of subcutaneous Nivolumab in serum, Up to 3 weeks|Area under the concentration-time curve within a dosing interval (AUC(TAU)) of subcutaneous Nivolumab in serum, Up to 3 weeks|Concentration at the end of a dosing interval (Ctau) of subcutaneous Nivolumab in serum, Up to 3 weeks|Trough observed concentration (Ctrough) of subcutaneous Nivolumab, At Cycle 7 Day 1 (Week 18)
Number of participants with adverse events (AEs), Up to approximately 2.5 years|Number of participants with serious adverse events (SAEs), Up to approximately 2.5 years|Number of participants with drug related AEs, Up to approximately 2.5 years|Number of participants with Immune Mediated Adverse Events (IMAEs), Up to approximately 2.5 years|Number of participants with AEs leading to discontinuation, Up to approximately 2.5 years|Number of deaths, Up to approximately 2.5 years|Number of participants with anti-nivolumab antibodies, Up to approximately 2.5 years|Number of participants with anti-ipilimumab antibodies, Up to approximately 2.5 years|Number of participants with neutralizing antibodies, Up to approximately 2.5 years|Cmax of intravenous Ipilimumab in serum, Up to 6 weeks|Tmax of intravenous Ipilimumab in serum, Up to 6 weeks|AUC(TAU) of intravenous Ipilimumab in serum, Up to 6 weeks|Ctau of intravenous Ipilimumab in serum, Up to 6 weeks
The purpose of this study is to evaluate two dosing regimens of subcutaneous Nivolumab in combination with intravenous Ipilimumab and chemotherapy in participants with previously untreated metastatic or recurrent Non-Small Cell Lung Cancer (NSCLC)